The stock of ABUS gained significantly in the pre-market after the company was upgraded from hold to buy by the analyst firm Jefferies. ABUS values at $3.10, gaining more than 6.16% from the previously closed value. The stock closed at $2.92 at the end of the last trading session. The stock volume traded in the previous trading session was around 3.48 million shares.
ABUS upgraded from hold to buy by Jefferies
Arbutus Biopharma Corporation’s (ABUS) shares have been upgraded from a hold to a buy by the analyst firm Jefferies. As of February 1, 2022, the business anticipates that the stock of Arbutus Biopharma Corporation (ABUS) will have increased by about 71 percent from its previous closing price. On February 1, 2022, the stock reached a high of $2.92.
The stock analysts at Jefferies anticipate that the price of ABUS stock will rise from $2.92 to between $4 and $5 per common stock share, up from its current price of $2.92.
The company has just provided its corporate and financial objectives and their financial results on January 24, 2022. Arbutus Biopharma Corporation (ABUS) has released a list of anticipated critical milestones, with the first of these expected in the second half of 2022.
The effect on the ABUS stock
Arbutus Biopharma Corporation (ABUS) was hot in the pre-market trading session. Investors are responding positively to the buy status by Jefferies. When the regular trading session starts, the stock is expected to increase as the pre-market hours become more volatile. Investors prefer to trade in the regular trading session. That is why the stock may surge more than the current value in the pre-market.
Conclusion
ABUS is going upward as soon as the news hits the market. The company is expecting some positive results in 2022. Arbutus Biopharma expects a significant gain in the financial number, due to which the analyst has ranked it a strong buy with a 71% increase in the value.
